12:00 AM
Sep 08, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AS1411: Phase II started

Antisoma began an open-label, U.S. Phase II trial to evaluate 40 mg/kg/day of IV AS1411 as monotherapy in 30 patients intolerant to, or relapsed...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >